{"artifact":{"id":"paper-fig-983c1e5c-f3cb-4090-afda-7d4346861ce5-2","artifact_type":"paper_figure","entity_ids":"[]","title":"Figure 2 — Monoclonal Antibodies as a Therapeutic Strategy against Multidrug-Resistant Bact","quality_score":0.5,"created_by":"paper_figures_tool","provenance_chain":"[{\"step\": \"paper_figures_backfill\", \"pmid\": \"983c1e5c-f3cb-4090-afda-7d4346861ce5\", \"timestamp\": \"2026-04-22T01:29:41.253933\"}]","content_hash":null,"metadata":{"pmid":"983c1e5c-f3cb-4090-afda-7d4346861ce5","caption":"Multifaceted mechanisms of mAbs against bacterial infections. This figure illustrates the complex mechanisms through which mAbs counteract bacterial infections. ( A ) Highlights the neutralization or inhibition of bacterial virulence factors by mAbs, mitigating their pathogenic effects. ( B ) The process of mAbs blocking receptor-mediated adhesion is depicted, preventing bacterial adherence to host cells and hindering the progression of infection. ( C ) Portrays the Antibody–Antibiotic Conjugate (ADC) strategy, where mAbs conjugated with antibiotics enhance the precision and effectiveness of bacterial targeting and elimination. ( D ) Focuses on the role of mAbs in inhibiting or disrupting biofilm formation, a primary bacterial defense mechanism, facilitating bacterial clearance. ( E ) Illustrates the mAb-mediated NETosis/opsonophagocytosis pathway, promoting bacterial clearance through the facilitation of neutrophil extracellular traps (NETs) and enhanced phagocytosis. ( F ) Delineates","image_url":"https://www.ebi.ac.uk/europepmc/articles/PMC10890110/bin/life-14-00246-g002.jpg","paper_title":"Monoclonal Antibodies as a Therapeutic Strategy against Multidrug-Resistant Bacterial Infections in a Post-COVID-19 Era.","figure_label":"Figure 2","figure_number":2,"_schema_version":1,"source_strategy":"pmc_api"},"created_at":"2026-04-21T18:29:40.747630-07:00","updated_at":"2026-04-21T18:29:40.747630-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"external","origin_url":null,"lifecycle_changed_at":"2026-04-21T18:29:40.747630-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"f992e58d-a0c2-4aac-bd3b-7c3e61e0ea83","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"paper_figures_tool"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[],"current_artifact_id":"paper-fig-983c1e5c-f3cb-4090-afda-7d4346861ce5-2","is_canonical":true,"supersede_chain":["paper-fig-983c1e5c-f3cb-4090-afda-7d4346861ce5-2"]}